[HTML][HTML] Pulmonary arterial hypertension: Emerging principles of precision medicine across basic science to clinical practice
NJ Kelly, SY Chan - Reviews in cardiovascular medicine, 2022 - ncbi.nlm.nih.gov
Pulmonary arterial hypertension (PAH) is an enigmatic and deadly vascular disease with no
known cure. Recent years have seen rapid advances in our understanding of the molecular …
known cure. Recent years have seen rapid advances in our understanding of the molecular …
Translational Advances in the Field of Pulmonary Hypertension.Focusing on Developmental Origins and Disease Inception for the Prevention of Pulmonary …
Persistent challenges in managing pulmonary vascular disease progression and poor
outcomes, despite the aggressive use of current drug therapies, highlight the need for …
outcomes, despite the aggressive use of current drug therapies, highlight the need for …
Translational Advances in the Field of Pulmonary Hypertension Molecular Medicine of Pulmonary Arterial Hypertension. From Population Genetics to …
An improved understanding of the molecular causes and modifiers of pulmonary arterial
hypertension (PAH) has emerged during the last several decades. However, the survival of …
hypertension (PAH) has emerged during the last several decades. However, the survival of …
Pulmonary arterial hypertension: challenges in translational research and a vision for change
G Sutendra, ED Michelakis - Science translational medicine, 2013 - science.org
Pulmonary arterial hypertension (PAH) is a vascular remodeling disease with a relentless
course toward heart failure and early death. Existing PAH therapies, all of which were …
course toward heart failure and early death. Existing PAH therapies, all of which were …
Advances in the management of pulmonary arterial hypertension
H Deshwal, T Weinstein… - Journal of Investigative …, 2021 - journals.sagepub.com
The management of pulmonary arterial hypertension (PAH) has significantly evolved over
the last decades in the wake of more sensitive diagnostics and specialized clinical programs …
the last decades in the wake of more sensitive diagnostics and specialized clinical programs …
The potential application and promising role of targeted therapy in pulmonary arterial hypertension
MCW Hsieh, WT Wang, JL Yeh, CY Lin, YR Kuo… - Biomedicines, 2022 - mdpi.com
Pulmonary arterial hypertension (PAH) is a rare yet serious progressive disorder that is
currently incurable. This female-predominant disease unfolds as a pan-vasculopathy that …
currently incurable. This female-predominant disease unfolds as a pan-vasculopathy that …
Pathobiology of pulmonary arterial hypertension: understanding the roads less travelled
AR Hemnes, M Humbert - European Respiratory Review, 2017 - Eur Respiratory Soc
The pathobiology of pulmonary arterial hypertension (PAH) is complex and incompletely
understood. Although three pathogenic pathways have been relatively well characterised, it …
understood. Although three pathogenic pathways have been relatively well characterised, it …
Pulmonary arterial hypertension–progress in understanding the disease and prioritizing strategies for drug development
P Ghataorhe, CJ Rhodes, L Harbaum… - Journal of Internal …, 2017 - Wiley Online Library
Pulmonary arterial hypertension (PAH), at one time a largely overlooked disease, is now the
subject of intense study in many academic and biotech groups. The availability of new …
subject of intense study in many academic and biotech groups. The availability of new …
Novel techniques for advancing our understanding of pulmonary arterial hypertension
EM Beck, ND Hatton, JJ Ryan - European Respiratory Journal, 2019 - Eur Respiratory Soc
Pulmonary arterial hypertension (PAH) is a rare disease of the pulmonary vasculature
characterised by progressive remodelling and narrowing of the pulmonary arteries due to …
characterised by progressive remodelling and narrowing of the pulmonary arteries due to …
Pulmonary arterial hypertension: pathophysiology and treatment
NSH Lan, BD Massam, SS Kulkarni, CC Lang - Diseases, 2018 - mdpi.com
Pulmonary arterial hypertension (PAH), the first category of pulmonary hypertension, is a
chronic and progressive disorder characterised by angioproliferative vasculopathy in the …
chronic and progressive disorder characterised by angioproliferative vasculopathy in the …
相关搜索
- precision medicine clinical practice
- precision medicine basic science
- clinical practice basic science
- pulmonary hypertension disease inception
- pulmonary hypertension translational advances
- precision medicine translational advances
- pulmonary hypertension developmental origins
- precision medicine gene editing
- precision medicine population genetics